{"id":"fluzoparib-capsules","safety":{"commonSideEffects":[{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Leukopenia"}]},"_chembl":{"chemblId":"CHEMBL3930624","moleculeType":"Small molecule","molecularWeight":"472.40"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PARP inhibitors like fluzoparib trap PARP proteins on DNA and prevent the repair of single-strand breaks, which accumulate into lethal double-strand breaks in cancer cells. This mechanism is particularly effective in tumors with BRCA1/2 mutations or homologous recombination deficiency, where alternative DNA repair pathways are already compromised. The drug forces cancer cells into apoptosis while having relatively less impact on normal cells with intact DNA repair mechanisms.","oneSentence":"Fluzoparib is a PARP inhibitor that blocks poly(ADP-ribose) polymerase enzymes, preventing DNA repair in cancer cells and leading to cell death.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:13:08.645Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"BRCA-mutated ovarian cancer"},{"name":"BRCA-mutated breast cancer"},{"name":"Homologous recombination deficient ovarian cancer"}]},"trialDetails":[{"nctId":"NCT07321015","phase":"PHASE2","title":"A Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast Cance","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-01-20","conditions":"Platinum-sensitive, TNBC, Triple Negative Breast Cancer, BRCA1/2 Mutation or Not","enrollment":72},{"nctId":"NCT06255392","phase":"PHASE3","title":"Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-06-12","conditions":"Fludzoparib" and Anti-angiogenic, HRD-positive/HER2-negative Advanced Breast Cancer","enrollment":200},{"nctId":"NCT06208410","phase":"PHASE1, PHASE2","title":"A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors","status":"RECRUITING","sponsor":"Risen (Suzhou) Pharma Tech Co., Ltd.","startDate":"2024-01-11","conditions":"Advanced Solid Tumors","enrollment":306},{"nctId":"NCT03863860","phase":"PHASE3","title":"A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2019-04-30","conditions":"Ovarian Cancer","enrollment":252},{"nctId":"NCT06954584","phase":"PHASE3","title":"Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-05-27","conditions":"Ovarian Cancer","enrollment":424},{"nctId":"NCT04691804","phase":"PHASE3","title":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-03-18","conditions":"Metastatic Castration-Resistant Prostate Cancer (mCRPC)","enrollment":496},{"nctId":"NCT06735326","phase":"PHASE2","title":"Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer","status":"RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2024-11-27","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer","enrollment":105},{"nctId":"NCT06541314","phase":"PHASE2","title":"Fluzoparib Neoadjuvant Therapy for Ovarian Cancer","status":"RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2024-06-18","conditions":"Ovarian Cancer","enrollment":48},{"nctId":"NCT06539091","phase":"PHASE3","title":"Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer","status":"NOT_YET_RECRUITING","sponsor":"Anhui Provincial Hospital","startDate":"2024-10-01","conditions":"Epithelial Ovarian Cancer, Efficacy, Safety","enrollment":51},{"nctId":"NCT06413992","phase":"PHASE2","title":"Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-05-10","conditions":"Endometrial Carcinoma, TP53 Mutation, Recurrent or Metastatic","enrollment":117},{"nctId":"NCT04300114","phase":"PHASE3","title":"A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy","status":"TERMINATED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2020-08-19","conditions":"Metastatic Pancreatic Cancer","enrollment":5},{"nctId":"NCT06188455","phase":"PHASE3","title":"Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2024-12-01","conditions":"Ovarian Cancer","enrollment":37},{"nctId":"NCT06161272","phase":"PHASE2","title":"Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi","status":"UNKNOWN","sponsor":"Guangxi Medical University","startDate":"2023-12-10","conditions":"Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma","enrollment":80},{"nctId":"NCT06063070","phase":"PHASE2","title":"First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-10-18","conditions":"Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, High Grade Endometrioid Ovarian Cancer","enrollment":44},{"nctId":"NCT05732129","phase":"PHASE2","title":"The Efficacy and Safety of Fluzoparib Plus Irinotecan as Second-line Treatment in Patients With Homologous Recombination Deficiency (HRD) Metastatic Colorectal Cancer.","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2023-03-01","conditions":"Homologous Recombination Deficiency Alterations Metastatic Colorectal Cancer","enrollment":29},{"nctId":"NCT03182673","phase":"PHASE1","title":"The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2017-07-24","conditions":"Solid Tumor","enrollment":31},{"nctId":"NCT03945604","phase":"PHASE1","title":"A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2019-06-04","conditions":"Triple Negative Breast Cancer","enrollment":32},{"nctId":"NCT03509636","phase":"PHASE1","title":"A Study of Fluzoparib（SHR-3162）in BRCA1/2-mutant Relapsed Ovarian Cancer","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2018-04-04","conditions":"Ovarian Cancer","enrollment":113},{"nctId":"NCT03075462","phase":"PHASE1","title":"A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2017-03-09","conditions":"Ovarian Cancer, Triple Negative Breast Cancer","enrollment":98},{"nctId":"NCT05349409","phase":"PHASE2","title":"A Trial of the Combination of SHR-A1811 and Fluzoparib in HER2-Expressing Cancers","status":"UNKNOWN","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2022-06-09","conditions":"Advanced Solid Tumors","enrollment":212},{"nctId":"NCT04041011","phase":"PHASE1","title":"A Study of SHR-1316 and Fluzoparib（SHR-3162） in Small Cell Lung Cancer Patients","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2019-09-17","conditions":"Small Cell Lung Cancer","enrollment":23},{"nctId":"NCT04521192","phase":"PHASE1","title":"Bioequivalence of Fluzoparib(SHR3162) Study on Healthy Chinese Adult Subjects","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2019-05-06","conditions":"Healthy Adult Subjects","enrollment":40},{"nctId":"NCT02759666","phase":"PHASE1","title":"A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Atridia Pty Ltd.","startDate":"2016-06-01","conditions":"Neoplasm, Solid Tumors","enrollment":30},{"nctId":"NCT02575651","phase":"PHASE1","title":"A Phase I Study of Fluzoparib in Patient With Advanced Solid Malignancies","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2015-04","conditions":"Advanced Solid Malignancies","enrollment":79},{"nctId":"NCT03645200","phase":"PHASE1","title":"Treatment of Carrying TP53 Harmful Mutations","status":"UNKNOWN","sponsor":"Tianjin Medical University Second Hospital","startDate":"2019-07-01","conditions":"Advanced Cancer","enrollment":60},{"nctId":"NCT03026881","phase":"PHASE1","title":"A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2017-01","conditions":"Recurrent and Metastatic Gastric Cancer","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["SHR-3162","Poly (ADP-ribose) polymerase (PARP) inhibitor"],"phase":"phase_3","status":"active","brandName":"Fluzoparib Capsules","genericName":"Fluzoparib Capsules","companyName":"The First Affiliated Hospital of Xiamen University","companyId":"the-first-affiliated-hospital-of-xiamen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fluzoparib is a small molecule used in clinical trials for various cancer types, including recurrent and metastatic gastric cancer, triple negative breast cancer, and ovarian cancer. It is being studied in combination with apatinib and paclitaxel in a phase I clinical trial.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}